Show results for
Refine by
Drug Platform Equipment & Supplies In Congo
31 equipment items found
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
by:Taiwan Liposome Company, Ltd. (TLC) based inNangang Distric, TAIWAN
TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with entirely unique properties. TLC has proprietary solution for pharmaceutical product development called LipAD®. LipAD® allows the design of medicines at the nanometer scale, improving drug solubility, protecting molecules from degradation, or targeting drug delivery to ...
by:Theramx Inc. based inSeongnam-si, SOUTH KOREA
Drug delivery platform technology designed to maximize efficacy while simultaneously minimizing side effects of existing drugs by delivery to desired ...
Manufactured by:Cytocast based inBudapest, HUNGARY
Cytocast is at the forefront of medical technology with its innovative Cytocast Digital Twin Platform™, a pioneering solution in drug development and personalized medicine. At its core is the CYTOCAST DIGITAL TWIN Cell™, a highly detailed simulated human cell model encompassing 15 tissue types. The platform integrates multi-omics data ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs ...
Manufactured by:Exparel based inParsippany, NEW JERSEY (USA)
EXPAREL uses proprietary multivesicular liposome (pMVL) technology, an advanced drug delivery platform, to extend analgesia. ...
Manufactured by:Rebiotix Inc., a Ferring Company based inRoseville, MINNESOTA (USA)
Rebiotix Inc., a Ferring Company, has leveraged its clinical, manufacturing and regulatory experience with RBX2660 to develop the first of its kind non-frozen, room temperature stable oral microbiota-based formulation under the MRT™ drug platform, known as RBX7455. While it is currently used to reduce the incidence of recurrent Clostridioides difficile ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
The drug candidate GS-659, which is sprung from Gesynta Pharma’s drug development platform, is currently in preclinical development phase. Project updates will be announced in due ...
Manufactured by:Rebiotix Inc., a Ferring Company based inRoseville, MINNESOTA (USA)
Rebiotix Inc., a Ferring Company, has conducted several trials of the lead microbiota-based product in the MRT drug platform, RBX2660, for reducing the rate of recurrence of Clostridioides difficile infection. RBX2660 is currently under study in a Phase 3 clinical trial in conjunction with the US Food and Drug Administration’s ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
The XF drug platform has a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistant to its action. Destiny Pharma’s XF platform has advantages over traditional antibiotics. ...
Manufactured by:Skyepharma Production SAS based inSaint-Quentin-Fallavier, FRANCE
Geomatrix® (multi-layer tablet technology) is a well-established, validated and customizable oral drug delivery platform technology that is currently used in 8 products that are commercialized in over 80 countries. Geomatrix® is highly versatile and can be applied to a wide range of different drugs to achieve a variety of different ...
Manufactured by:Intrommune Therapeutics based inNew York, NEW YORK (USA)
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be conveniently administered during a patient’s daily toothbrushing ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. ZymeLink™ is compatible with traditional antibodies, proteins, ...
Manufactured by:Benevolent based inLondon, UNITED KINGDOM
The emerging global threat from COVID-19 demanded immediate action. With cases rising rapidly, we set up a specialist team to use our AI-drug discovery platform to search for existing drugs — already proven safe — that could be repurposed to treat the virus. We are the only AI company to successfully identify a drug ...
Manufactured by:Base4 based inChicago, ILLINOIS (USA)
Exploiting RNA dynamics: RNAs rapidly exchange between a vast array of distinct 3D conformations, each revealing potentially novel binding surfaces. These dynamics are critical to understanding RNA function and fully exploiting its untapped drug potential. Our proprietary platform is built on unparalleled advancements in RNA structural biology that allows for the ...
Manufactured by:InSphero AG based inSchlieren, SWITZERLAND
When you’re ready, we deliver. InSphero assay-ready spheroid microtissues are engineered and certified for use in critical drug development applications, and validated to ensure uniform size, robust functionality, and reproducible results. We develop 3D InSight™ Microtissues using the most advanced 3D cell culture technologies available to produce highly predictive, ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
Innovation is at the heart of everything we do. Our proprietary drug delivery technology platform, Veltis®, uses engineered recombinant albumin to enhance albumin’s intrinsic characteristics for optimal therapeutic performance of your ...
by:Microba Life Sciences based inBrisbane City, AUSTRALIA
Developing novel therapeutics from the human microbiome; The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity. Microba has established a platform for drug discovery and development that leverages a growing, proprietary Databank of human microbiome samples and associated ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, GPCRs whose natural ligands are large peptides or small proteins are ...